Target intelligence / Profile preview

ELAV like RNA binding protein 4 (ELAVL4)

Target
ELAVL4
Molecular classification
RNA-binding protein, Post-transcriptional regulator, Other
01

Overview

ELAV like RNA binding protein 4 (ELAVL4), also commonly known as HuD, is a neuron-specific RNA binding protein that belongs to the Hu/ELAV family. It is crucial for post-transcriptional regulation of neuronal mRNAs, controlling mRNA stability, localization, and translation. ELAVL4 is expressed mainly in neurons and regulates a variety of neuronal processes, including development, plasticity, differentiation, axon outgrowth, and synapse formation. The protein contains RNA recognition motifs that bind AU-rich elements in mRNA 3’UTRs, stabilizing target transcripts and enhancing their translation. ELAVL4 plays an important role in nervous system development and function, and altered expression or regulation is linked to neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, ALS, and to paraneoplastic neurological syndromes, where anti-HuD autoantibodies are observed[1][3][5]. Although not considered a typical therapeutic target (such as a receptor or enzyme), ELAVL4 is a crucial regulator in neuronal biology and a recognized autoantigen in some neurological diseases[1][3][4][5].

Other names
HuDPNEMHUDParaneoplastic encephalomyelitis antigen HuDHu antigen D
02

Biological functions

Regulation of mRNA stabilityRegulation of mRNA localizationRegulation of translationRegulation of alternative splicingNeuronal differentiationAxon outgrowthSynapse formation
03

Disease associations

Neurodegenerative diseaseCancerOther (notably involved in paraneoplastic neurological syndromes and implicated in diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis)
04

Safety considerations

Potential target of autoimmune responses in paraneoplastic neurological diseases, rare risk of autoimmunity if targeted therapeutically[1].
05

Biomarkers

Antibodies against HuD (ELAVL4) are used as biomarkers in paraneoplastic neurological syndromes, including paraneoplastic encephalomyelitis[1].

Beyond the preview

Go deeper on ELAV like RNA binding protein 4 (ELAVL4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELAV like RNA binding protein 4 (ELAVL4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call